A Genotypic Method for Determining {HIV-2} Coreceptor Usage enables Epidemiological Studies and Clinical Decision Support by Döring, M. et al.
Döring et al. Retrovirology  (2016) 13:85 
DOI 10.1186/s12977-016-0320-7
RESEARCH
A genotypic method for determining 
HIV-2 coreceptor usage enables epidemiological 
studies and clinical decision support
Matthias Döring1* , Pedro Borrego2,3, Joachim Büch1, Andreia Martins2, Georg Friedrich1, 
Ricardo Jorge Camacho4, Josef Eberle5, Rolf Kaiser6, Thomas Lengauer1, Nuno Taveira2,7 and Nico Pfeifer1*
Abstract 
Background: CCR5-coreceptor antagonists can be used for treating HIV-2 infected individuals. Before initiating treat-
ment with coreceptor antagonists, viral coreceptor usage should be determined to ensure that the virus can use only 
the CCR5 coreceptor (R5) and cannot evade the drug by using the CXCR4 coreceptor (X4-capable). However, until 
now, no online tool for the genotypic identification of HIV-2 coreceptor usage had been available. Furthermore, there 
is a lack of knowledge on the determinants of HIV-2 coreceptor usage. Therefore, we developed a data-driven web 
service for the prediction of HIV-2 coreceptor usage from the V3 loop of the HIV-2 glycoprotein and used the tool to 
identify novel discriminatory features of X4-capable variants.
Results: Using 10 runs of tenfold cross validation, we selected a linear support vector machine (SVM) as the model 
for geno2pheno[coreceptor-hiv2], because it outperformed the other SVMs with an area under the ROC curve (AUC) 
of 0.95. We found that SVMs were highly accurate in identifying HIV-2 coreceptor usage, attaining sensitivities of 
73.5% and specificities of 96% during tenfold nested cross validation. The predictive performance of SVMs was not 
significantly different (p value 0.37) from an existing rules-based approach. Moreover, geno2pheno[coreceptor-
hiv2] achieved a predictive accuracy of 100% and outperformed the existing approach on an independent 
data set containing nine new isolates with corresponding phenotypic measurements of coreceptor usage. 
geno2pheno[coreceptor-hiv2] could not only reproduce the established markers of CXCR4-usage, but also revealed 
novel markers: the substitutions 27K, 15G, and 8S were significantly predictive of CXCR4 usage. Furthermore, SVMs 
trained on the amino-acid sequences of the V1 and V2 loops were also quite accurate in predicting coreceptor usage 
(AUCs of 0.84 and 0.65, respectively).
Conclusions: In this study, we developed geno2pheno[coreceptor-hiv2], the first online tool for the prediction of 
HIV-2 coreceptor usage from the V3 loop. Using our method, we identified novel amino-acid markers of X4-capable 
variants in the V3 loop and found that HIV-2 coreceptor usage is also influenced by the V1/V2 region. The tool can aid 
clinicians in deciding whether coreceptor antagonists such as maraviroc are a treatment option and enables epide-
miological studies investigating HIV-2 coreceptor usage. geno2pheno[coreceptor-hiv2] is freely available at http://
coreceptor-hiv2.geno2pheno.org.
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Background
Human immunodeficiency virus type 2 (HIV-2) is preva-
lent in Western Africa and specific European countries, 
such as France and Portugal [1]. In comparison to HIV-
1, HIV-2 exhibits a reduced infectivity [2], a lower rep-
licative capacity [3], and an increased susceptibility to 
antibody-mediated neutralization [4]. During the course 
of HIV-2 infection, CD4 declines slowly and the clinically 
latent phase can last for decades [5]. Still, infection with 
HIV-2 can lead to acquired immune deficiency syndrome 
(AIDS) [6] and effective antiretroviral treatments are cru-
cial for preventing disease progression.
Possible treatments for individuals infected with HIV-2 
are limited because many antiretrovirals are less effective 
inhibitors of HIV-2 than of HIV-1 [7–9]. HIV-2 is intrin-
sically resistant to non-nucleoside reverse transcriptase 
inhibitors [10, 11] and to the fusion inhibitor enfuvirtide 
[7, 12]. Additionally, from the class of protease inhibi-
tors, only saquinavir, lopinavir, and daruinavir are effec-
tive against HIV-2 [9]. Selecting an appropriate treatment 
regimen can be further exacerbated by the rapid devel-
opment of HIV-2 drug resistance [9, 13, 14]. Maraviroc, 
a CCR5 coreceptor antagonist, poses a new treatment 
option for individuals infected with HIV-2 [15–18]. The 
drug prevents viral cell entry by obstructing the CCR5 
coreceptor and should be administered only to patients 
infected with an R5-tropic virus to ensure treatment effi-
cacy and to prevent a switch to viral usage of the CXCR4 
coreceptor. Therefore, determining viral coreceptor usage 
is crucial before initiating treatment with coreceptor 
antagonists such as maraviroc [16]. Moreover, the identi-
fication of HIV-2 coreceptor usage can be useful for stag-
ing disease progression: CXCR4-using viruses, which are 
less susceptible to antibody neutralization than R5-tropic 
strains [19], are associated with low CD4+ T cell counts 
and progressed disease [20, 21].
Although some HIV-2 strains have been shown to 
infect cells without use of the CD4 receptor in  vitro [1, 
22, 23], HIV-2 enters cells in vivo by first binding to the 
CD4 receptor and then interacting with a coreceptor 
belonging to the family of chemokine receptors [24]. 
Similarly to HIV-1, CCR5 and CXCR4 are the major 
coreceptors that are used by HIV-2 in vivo [25, 26]. The 
variable loop 3 (V3) of the viral surface glycoprotein 
(known as gp125 or gp105) is crucial for coreceptor bind-
ing. Specific substitutions in the V3 loop are particularly 
indicative of X4-capability [27–30] and often bring forth 
an increased V3 net charge [21, 29, 31, 32].
Three viral variants can be delineated according to the 
coreceptor that is used during cell entry. R5-tropic viruses 
can use only the CCR5 coreceptor, X4-tropic viruses can 
use the CXCR4 coreceptor, and dual-tropic viruses can 
use both CCR5 and CXCR4. Patients harboring R5- and 
X4-tropic viruses simultaneously have mixed infections. 
Since mixed infections usually cannot be distinguished 
from infections with dual-tropic variants, the term dual/
mixed (D/M) is used to denote patients with a dual infec-
tion or a dual-tropic virus. To simplify the terminology, 
we define a virus/viral population as R5 if it can use only 
CCR5, while X4-capable defines a virus/viral popula-
tion that can use CXCR4 (possibly in addition to other 
coreceptors).
Viral coreceptor usage can be determined either pheno-
typically or genotypically. Phenotypic approaches often 
use engineered cell lines expressing only certain corecep-
tors on their surface such that they elicit a specific signal 
upon viral infection. For example, TZM-bl cells [33, 34] 
express firefly luciferase enzyme under the control of the 
HIV-1 promoter. Since TZM-bl cells express CD4, CCR5, 
and CXCR4, coreceptor usage can be measured by block-
ing one and/or both coreceptors with excessive amounts 
of coreceptor antagonists and evaluating the resulting 
luminescence [16, 35].
While phenotypic assays are accurate and engineered 
cell lines enable the detection of a broad range of core-
ceptor usage patterns, such assays are expensive, time-
consuming, and their interpretation can be challenging. 
For example, when evaluating the results from an assay 
based on TZM-bl cells, the residual viral replication in 
the presence of the applied coreceptor antagonists needs 
to be interpreted. Moreover, TZM-bl cell based assays 
using different coreceptor antagonists (e.g. maraviroc 
and TAK-779 for CCR5) might not yield exactly the same 
results for the same isolate. Additionally, phenotypically 
determined coreceptor usage might not accord with 
in  vivo coreceptor usage, because engineered cell lines 
exhibit larger surface densities of CD4 and HIV corecep-
tors than primary cells. Hence, a virus that cannot use a 
given coreceptor in  vivo may be falsely reported to use 
that coreceptor if cell entry is enabled by the increased 
avidity of the interactions between virus and engineered 
cell. In contrast to HIV-1, where the enhanced sensitivity 
Trofile assay provides a standardized means for identify-
ing coreceptor usage [36], there exists no standardized 
phenotypic assay for HIV-2. Instead, different pheno-
typic approaches are in use, which may lead to inconsist-
ent results. Genotypic methods, on the other hand, are 
not performed in a laboratory, but are based on detect-
ing discriminatory features in the viral genome. These 
approaches usually agree well with phenotypic tests [37], 
save time, and are much less expensive than phenotypic 
assays.
The first genotypic approach for the identification of 
HIV-2 coreceptor usage was put forth by Visseaux et al. 
[28]. Their study identified nine markers in the V3 loop 
exhibiting significant associations with coreceptor usage. 
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Four of these markers with sensitivities greater than 70% 
and specificities of 100% were selected to form the major 
genotypic determinants of X4-capable variants: the sub-
stitutions L18X (where X is any non-L amino acid) and 
V19K/R, any insertion after position 24, and a V3 net 
charge exceeding six. The other five substitutions (S22A/
F/Y, Q23R, I25L/Y, R28K, and R30K) with significant 
associations were termed minor markers. Their rules-
based system classifies an HIV-2 strain as X4-capable if 
its V3 amino-acid sequence contains at least one of the 
four major markers and otherwise as R5. Applying this 
approach to an independent data set yielded a sensitivity 
of 65% and a specificity of 100% for detecting X4-capable 
variants.
Our study had two goals. First, we wanted to provide 
a data-driven, genotypic tool for predicting whether an 
HIV-2 V3 amino-acid sequence originates from an R5 
or an X4-capable variant. More specifically, we strove to 
improve on the rules-based approach to coreceptor iden-
tification introduced by Visseaux et  al. [28]. Second, we 
wanted to investigate which V3 amino-acid mutations 
confer the X4-capable phenotype and determine whether 
amino-acid features in the V1/V2 region are also predic-
tive of coreceptor usage.
We demonstrate that viral coreceptor usage can 
be accurately predicted from specific amino-acid 
substitutions in the HIV-2 V3 loop and provide 
geno2pheno[coreceptor-hiv2], a web service for HIV-2 
coreceptor prediction. We were not only able to confirm 
previously established markers of X4-capability, but also 
found previously unreported V3 substitutions predictive 
of X4-capable viruses. Additionally, we found evidence 
indicating that the V1/V2 region also modulates HIV-2 
coreceptor usage.
Results
To generate statistical models capable of predicting 
HIV-2 coreceptor usage, we gathered a data set of 126 
pairs of HIV-2 genomic amino-acid sequences and phe-
notypic coreceptor usage annotations (either R5 or 
X4-capable). Based on this data set, we trained and vali-
dated support vector machines (SVMs) with various ker-
nel functions on the amino-acid sequences of either the 
V1, V2, V3, or all three regions and the corresponding 
coreceptor usage annotations to identify the most pre-
dictive models according to their areas under the ROC 
curve (AUCs). Due to its high predictive accuracy, we 
decided to use a linear SVM based on the V3 amino-acid 
sequence for all further analyses. Next, we validated an 
existing rules-based approach for HIV-2 coreceptor iden-
tification [28] and compared the predictive accuracy of 
this approach with the accuracy of SVMs.
To identify which substitutions in the V3 amino-acid 
sequence impart the X4-capable phenotype according to 
the linear SVM, we investigated the model weights and 
statistically tested the discriminatory strength of individ-
ual substitutions in the V3 loop. Last, we implemented 
the linear SVM as a web service, for which we trans-
formed predicted X4-probabilities to false positive rates 
(FPRs), selected a suitable FPR threshold, and created a 
visualization representing the model weights associated 
with an input sequence. To validate the implementation 
of the web service, we evaluated the predictive accuracy 
of geno2pheno[coreceptor-hiv2] on an independent set 
of nine new HIV-2 isolates with phenotypically deter-
mined coreceptor usage, which were not previously used 
for training the model.
Model selection and validation of SVMs
To predict HIV-2 coreceptor usage, we trained SVMs 
on data involving several regions of the HIV-2 genome. 
We decided to train SVMs on the V1, V2, and V3 loops 
as those regions are known to impact HIV-2 coreceptor 
usage most [27–30, 38]. We also trained an SVM on a 
combination of all three variable regions. To estimate the 
predictive performance of SVMs on unseen data, we per-
formed 10 runs of tenfold cross validation (CV) on the 
complete data set of 126 samples. Having partitioned the 
data set into 10 disjoint folds, the i-th (i ∈ {1, 2, . . . , 10} ) 
round of CV entails training a model using the samples 
contained in all folds except for the i-th fold and then val-
idating the model on the i-th fold. Linear models based 
on the V1 and V2 loops (N = 62) achieved AUCs of 0.84 
and 0.65, respectively. SVMs trained on V3 amino-acid 
sequences (N =  126) achieved similarly high accuracies 
for all kernel functions considered with the exception of 
the SVMs based on the edit kernel, which had distinctly 
smaller AUCs (see Table  1). The best-performing SVM 
that was trained on the V3 loop outperformed the mod-
els based on the V1/V2 regions (AUC of 0.95).
We also evaluated the performance of SVMs trained on 
62 samples using the amino-acid sequences of all three 
variable regions V1/V2/V3 and found that the best model 
performed worse (AUC of 0.89) than that based on the 
V3 loop alone. Due to the reduced predictive accuracy 
of models incorporating information from the V1/V2 
region, we decided to use the linear ν-SVM trained on 
126 V3 amino-acid sequences with the model parameter 
ν = 0.3 (AUC of 0.95) for geno2pheno[coreceptor-hiv2]. 
We refer to this SVM as the linear SVM in the following.
To identify the predictive performance of SVMs 
trained on V3 amino-acid sequences under considera-
tion of model selection bias, we also determined their 
tenfold nested CV performance. In the 10 inner runs, 
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SVMs using a linear kernel were chosen seven times and 
SVMs using an RBF kernel were chosen three times using 
their AUCs as a selection criterion. The AUC of tenfold 
nested CV was 0.88 (sensitivity of 76.9% and specificity 
of 97.3%).
Evaluation of the rules‑based approach for HIV‑2 
coreceptor identification
To evaluate the rules-based approach from Visseaux et al. 
[28] for identifying HIV-2 coreceptor usage, we deter-
mined the predictive accuracy of their approach on a 
subset of the complete data set called the test data set. 
The test data set was constructed to contain only those 
V3 sequences that had not been used for the identifica-
tion of the predictive rules used in their approach. We 
evaluated the rules-based approach from Visseaux et al. 
[28] for different numbers of required major markers 
of X4-capability (either 1, 2, 3, or 4) on the test data set 
(N =  84) and found that the balanced accuracy of pre-
diction decreased with increasing numbers of required 
major markers (balanced accuracies 0.89, 0.88, 0.85, and 
0.81, respectively). Hence, our evaluations confirm that 
requiring one major marker for X4-capability is the most 
accurate rules-based strategy, but the presence of addi-
tional markers can corroborate a prediction (Additional 
file 1: Table S1).
To determine the predictive performance of individual 
markers of X4-capability, we applied a two-sided Fish-
er’s exact test on the confusion matrices resulting from 
applying individual rules (Additional file  1: Table S2). 
After correcting for multiple hypothesis testing using the 
Benjamini–Hochberg procedure [39] at a false discovery 
rate of 5%, we found that among the established discrimi-
natory features only the substitutions R30K and I25L/Y 
were not significant predictors of X4-capability on the 
test data set at the 5% level.
Comparison of SVMs with the rules‑based approach
To compare the predictive performance of SVMs and the 
rules based approach [28], we validated both approaches 
on the test data set (N  =  84). The rules-based method 
from Visseaux et al. requiring just a single major rule to 
predict X4-capability [28] achieved a sensitivity of 85.3% 
and a specificity of 94% (balanced accuracy 89.6%). In 
comparison, tenfold nested CV of SVMs performed on 
the test data set resulted in a sensitivity of 73.5% and a 
specificity of 96% (balanced accuracy 84.7%), which is not 
significantly different (p value 0.37) to the rules-based 
predictions according to McNemar’s test [40].
Discriminatory features in the V3 loop
To analyze discriminatory features in the V3 loop, we cre-
ated a profile alignment of the V3 amino-acid sequences 
in the test data set and enumerated the positions in the 
V3 loop according to the HIV-2 reference strain M33262 
[41–43]. Many sequences from X4-capable viruses exhib-
ited more than one major marker for X4-capability. Of 
the 34 X4-capable sequences in the test data set, only 5 
(14.7%) samples did not have any marker, 2 (5.9%) had a 
single marker, 2 (5.9%) had two markers, 4 (11.8%) had 
three markers, and 21 (61.8%) had four markers. Interest-
ingly, the five X4-capable sequences without any markers 
for CXCR4 usage (accession numbers/isolate identifiers: 
DQ213035 [27], GU204944 [32], consensus V3 loop from 
clones JX219591-JX219598, GB87 [31], 310248 [31]) 
could neither be identified as X4-capable by the rules-
based method nor by geno2pheno[coreceptor-hiv2].
We investigated how well the linear SVM used for 
geno2pheno[coreceptor-hiv2] reproduces the nine pre-
viously described markers for X4-capability [28]. To 
this end, we visualized the predicted X4-probabilities 
of the linear SVM for sequences exhibiting these estab-
lished discriminatory features (Fig.  1) and evaluated 
the SVM features contributing 75% of the total model 
weights (Table 2). We found that the SVM predicted high 
X4-probabilities for sequences from X4-capable viruses 
exhibiting established X4-markers, which indicates that 
the SVM captures the established features of X4-capa-
ble variants well. However, because some R5 sequences 
also exhibit markers of X4-capability (particularly L18X, 
V19K/R, or a V3 net charge >6), these isolates were 
falsely predicted to use CXCR4 with a high probability.
By analyzing the SVM model coefficients, we iden-
tified novel, discriminatory features associated with 
Table 1 Classifier AUCs per run of cross validation
The column names indicate the kernel function corresponding to each SVM 
and kernel parameters are indicated in brackets. Only the results for the best-
performing kernel function (in terms of average AUC across all CV runs) for each 
set of evaluated parameters are shown. All of the classifiers performed best with 
a setting of ν = 0.3







1 0.9475 0.9459 0.941 0.8629
2 0.9509 0.9506 0.9452 0.851
3 0.9504 0.9579 0.9444 0.8655
4 0.9449 0.947 0.9379 0.8634
5 0.9472 0.9467 0.9413 0.8744
6 0.9467 0.9467 0.9457 0.8689
7 0.9532 0.9535 0.9475 0.8377
8 0.9522 0.9532 0.9306 0.8623
9 0.9524 0.9524 0.9478 0.9012
10 0.9441 0.9431 0.9384 0.8672
μ 0.949 0.9497 0.942 0.8654
σ 0.0033 0.0045 0.0053 0.0162
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X4-capability. The substitutions 27K, 15G, and 8S were 
significantly predictive of X4-capability according to 
Fisher’s exact test at the 5% level after multiple hypoth-
esis testing correction with the Benjamini–Hochberg 
procedure (Table 2).
Predicted X4‑probabilities and false positive rates
The distribution of predicted X4-probabilities result-
ing from applying the linear SVM on the complete data 
set (N = 126) using 10 runs of tenfold CV shows that V3 
loops from R5- and X4-capable viruses are, for the most 
part, well separable (Additional file  1: Figure S1). The 
region of low X4-probabilities is interspersed with sam-
ples from X4-capable viruses, which indicates that the 
SVM falsely identifies X4-capable viruses as R5 in some 
cases.
To find an FPR cutoff producing a satisfactory sepa-
ration of the predicted X4-probabilities from samples 
labeled as R5 and X4-capable, we performed k-means 
clustering on the X4-probabilities after we had found 
k = 2 by applying the elbow test on the within sum 
of squares error [44]. From the cluster represent-
ing X4-capable viruses, we then selected the minimal 
predicted probability for X4-capability (53.4%) and 
determined the corresponding FPR (3.4%). For better 
memorability, we decided to set the recommended cutoff 
for HIV-2 coreceptor prediction to an FPR of 5%, which 
increases the number of false alerts only slightly (Addi-
tional file 1: Figure S2).
The geno2pheno[coreceptor‑hiv2] web service
We implemented our predictive approach for the iden-
tification of HIV-2 coreceptor usage as a web service, 
which is available at http://coreceptor-hiv2.geno2pheno.
org. After inputting one or multiple nucleotide/amino-
acid sequences containing the V3 loop (at most 500) and 
selecting an FPR cutoff, the sequences are aligned to a 
profile of the V3 loop and coreceptor usage is predicted 
using the linear SVM. To interpret the results, the input 
sequences are compared to the HIV-2 reference strain 
M33262 [41–43]. The tool produces a PDF report show-
ing the aligned V3 loops, provides a csv-file that tabulates 
the predictions for batch runs, and visualizes the model 
coefficients of the input sequences (Fig.  2). The visuali-
zation shows the extent to which individual amino-acid 
substitutions influence a prediction and enables users to 
gauge the evidence pointing towards a certain prediction.
Validation of the geno2pheno[coreceptor‑hiv2] web 
service on an independent test set
We validated the predictive performance of the 
geno2pheno[coreceptor-hiv2] web service on an 
independent test set containing nine additional 
V3 samples that were not contained in the data set 
(N  =  126) that had been used to form the linear SVM 
of geno2pheno[coreceptor-hiv2]. Predictions from 
geno2pheno[coreceptor-hiv2] were compared to the 
phenotypically measured coreceptor usages for the nine 
samples, which had been determined using an assay 
based on TZM-bl cells. With the recommended FPR 
cutoff of 5%, all of the nine sequences were classified 
correctly (Table  3). The genotypic tool from Visseaux 
et  al. performed slightly worse on these sequences: The 
R5-sequence ROD10 (H18L + H23Δ + Y24Δ) was incor-
rectly classified as X4-capable due to its net charge of +7 
and the X4-capable sequence ROD10 (H18L  +  K29T) 
was classified incorrectly as R5, because it did not 
exhibit any of the major markers for X4-capability. 
Investigating the model coefficients of isolate ROD10 
(H18L + K29T) in Fig. 2 reveals one of the strengths of 
geno2pheno[coreceptor-hiv2]. In contrast to rules-based 
approaches, geno2pheno[coreceptor-hiv2] takes into 
account all V3 amino acid positions, which enables the 
Fig. 1 X4-probabilities predicted by geno2pheno[coreceptor-hiv2] 
for V3 amino-acid sequences exhibiting the established discrimina-
tory features indicative of X4-capability listed on the x-axis. The 
left-hand panel shows the predicted X4-probabilities for sequences 
labeled as R5, while the right-hand panel shows the predicted 
X4-probabilities for sequences labeled as X4-capable. The bottom line 
of a box indicates the 1st quartile (Q1) of predicted X4-probabilities, 
the bar inside the box indicates the median, and the top line indicates 
the 3rd quartile (Q3). The whiskers extending from a box indicate 
predicted X4-probabilities that lie within 1.5× IQR (interquartile 
range, IQR = Q3 − Q1). Outlier values that are not within the whisker 
region are shown as dots. Note that some of the sequence character-
istics indicated on the x-axis do not have a predicted X4-probability, 
because no sequences exhibiting the corresponding feature and 
phenotype were available
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identification of coreceptor usage for viruses where a 
combination of substitutions enables CXCR4 usage. For 
example, for the ROD10 (H18L  +  K29T) mutant, the 
combination of multiple negative weights associated with 
the features R2K, P11K, V12K, T13M, I14L, insertions 
after position 22, and N26N resulted in the prediction of 
X4-capability, rather than fulfilling individual rules.
Discussion
We were able to confirm the role of the HIV-2 V3 loop 
as the major determinant for the usage of the CCR5 and 
CXCR4 coreceptors. On the largest data set for HIV-2 
coreceptor usage available to us, high predictive per-
formances of rules-based and data-driven approaches 
for coreceptor identification were demonstrated. Using 
SVMs, we were not only able to replicate all of the estab-
lished markers of X4-capable variants, but could also 
identify additional markers with significant predictivity 
that have not been described previously.
Our results substantiate three characteristics differenti-
ating the HIV-2 and HIV-1 V3 loops with respect to core-
ceptor usage. While individual mutations in the HIV-2 
V3 loop by themselves are highly predictive of coreceptor 
usage (e.g. 18X has a sensitivity of 79% and a specificity of 
96%), there is no discriminatory signal in the HIV-1 V3 
loop that allows for the accurate identification of core-
ceptor usage by itself. For example, the 11/25 rule, which 
classifies HIV-1 as X4-capable if its V3 loop contains 
positively charged amino acids at the 11th or 25th posi-
tion [45], is highly specific (93%) but severely lacks sensi-
tivity (30%) [46]. Second, while the major discriminatory 
markers indicating CXCR4 usage of HIV-2 (18X, 19K/R, 
insertions after position 24) appear at the V3 C-terminus, 
discriminatory features of HIV-1 coreceptor usage occur 
along the full extent of the V3 region. Third, while a V3 
net charge exceeding six is significantly associated with 
the usage of CXCR4 by HIV-2 (Additional file  1: Table 
S2) [28], there is no significant association between the 
overall charge of the HIV-1 V3 loop and coreceptor usage 
[47], although CCR5 and CXCR4 exhibit contrasting 
electrostatic potential surfaces [48].
Our analysis of the predictive performance of SVMs 
based on various kernel functions revealed that linear 
kernel functions are well suited for HIV-2 coreceptor 
usage prediction and that kernel functions capturing 
higher-order interactions do not offer additional ben-
efits in this prediction scenario. These results suggests 
that HIV-2 coreceptor usage is largely based on individ-
ual amino-acid mutations in the V3 loop rather than on 
interdependent substitutions of amino acids as in HIV-1 
[49]. This finding would be supported by the hypoth-
esized open structure of the HIV-2 V3 loop, which might 
reduce the role of interactions among the amino acids in 
the V3 loop [27]. Determining and analyzing the struc-
ture of gp125 with an intact and ordered V3 loop would 
be a crucial step in confirming the independence of posi-
tions by elucidating the accessibility of the V3 loop [50].
We found further evidence [38] indicating that other 
envelope regions besides V3 might contribute to HIV-2 
coreceptor usage. First, SVMs based on the V1 and V2 
regions achieved substantial predictive accuracies. Sec-
ond, the V3 sequences of some X4-capable viruses did 
not exhibit any known features indicative of CXCR4 
usage (accession numbers/isolate identifiers: DQ213035 
[27], GU204944 [32], consensus V3 loop from clones 
JX219591-JX219598, GB87 [31], 310248 [31]) and some 
Table 2 Features in the model with the strongest impact on predicted viral coreceptor usage
Positions of discriminatory features that were not described previously are shown in bold italics
Position R5 feature X4 feature R5 weights X4 weights
18 L H, Q, F, M 0.69 −0.23, −0.15, −0.12, −0.1
Insertion after position 24 – I, V 0.45 −0.22, −0.21
19 I R, K, V 0.19 −0.25, −0.23, −0.19
Insertion after position 22 – H, Y 0.36 −0.18, −0.18
24 P NA 0.17 NA
23 Q R 0.14 −0.14
27 Q K 0.09 −0.12
13 T R 0.11 −0.07
26 NA N NA −0.09
10 A K 0.09 −0.07
14 I L 0.08 −0.08
22 S NA 0.08 NA
15 A G 0.08 −0.07
8 K S 0.07 −0.07
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V3 sequences of R5-tropic isolates exhibited markers 
of X4-capability (Fig.  1). Third, there are several sam-
ples sharing the same V3 loop, but exhibiting discordant 
measurements of phenotypic coreceptor usage (Addi-
tional file 1: Table S3). Note however that discordant phe-
notypic assignment of coreceptor use could also be the 
result of varying sensitivities among the different pheno-
typic assays (e.g. GHOST (3) cells, PBMCs with the Δ32 
mutation, U87 cells) as well as experimental conditions. 
In case that phenotypically determined coreceptor usage 
is inconclusive, clarification could be obtained by geno-
typic approaches such as geno2pheno[coreceptor-hiv2].
R5-tropic HIV-2 viruses exhibiting X4-markers could 
also be explained by a switch from CXCR4 to CCR5 
usage (X4-R5 reversion). X4-R5 reversions have already 
been reported in HIV-1-infected patients after immune 
reconstitution [51–54]. Because recent findings indicate 
that X4-capable HIV-1 viruses are less susceptible to 
neutralization by autologous antibodies than R5-using 
viruses from the same host [55], X4-R5 reversions could 
result from the normalization of naïve T-cell turnover 
following immunological recovery [56], after which the 
infection of naïve T-cells by X4-capable variants may not 
be productive enough [51]. Since X4-capable HIV-2 also 
seem to be less susceptible to neutralization than CCR5-
using strains [19], X4-R5 reversions in HIV-2 could be 
explained by the same mechanism.
Besides these interpretations, discrepancies between 
the measured phenotypic coreceptor usage and fea-
tures in the V3 amino-acid sequence could also be a 
Fig. 2 Visualization of the model coefficients for the V3 loop of the mutant ROD10 isolate (H18L + K29T). Amino acids with positive coefficients are 
associated with R5-tropic viruses, while negative coefficients are associated with X4-capable variants. The legend on the right indicates the color-
coded amino acids and gives the FPR of the prediction. Because the predicted FPR is below the selected cutoff at 5%, the sequence is predicted 
to be X4-capable, which is indicated by the dark color of the X4-capable label in the bottom left corner. The labels of the x-axis refer to the positions 
and amino acids of the HIV-2 reference strain M33262. Note that since the input sequence contains two insertions relative to the reference (H and Y 
after position 22), the 29T mutation is visualized at the x-axis tick with the D27 label
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by-product of the qualitative interpretation of pheno-
typic assays. In  vivo, coreceptor usage is on a continu-
ous scale and several, consecutive structural changes 
within the surface glycoprotein occurring along the viral 
evolutionary trajectory allow for increasingly effective 
coreceptor usage. However, this fact is neglected when 
the results of phenotypic assays are reported. Although 
the assays produce quantitative measurements (e.g. 
fluorescence, luminescence, or formation of syncytia), 
these measurements are typically converted to a qualita-
tive scale for the sake of convenience regarding further 
analyses. Typical qualitative scales are the annotation of 
coreceptor usage (e.g. R5/X4-capable) or the efficiency 
of coreceptor usage (e.g. −/+/++/+++). For the sake of 
accuracy, however, it would be paramount to work on the 
raw, quantitative data. With quantitative measurements, 
it would be possible to place a virus onto the evolutionary 
continuum stretching from viruses using CCR5 highly 
efficiently to viruses capable of using CXCR4. Moreover, 
working on raw data from phenotypic assays would facili-
tate the application of established statistical techniques 
for the normalization of biased data arising from sev-
eral experiments, which could improve the accuracy of 
large-scale studies on coreceptor usage considerably. Our 
genotypic analyses of several ROD10 mutants are a step 
in the right direction, because we were able to determine 
the impact of individual V3 substitutions on coreceptor 
usage quantitatively through the genotypic prediction of 
FPRs (Table 3).
To shed more light on the emergence of V3 amino-acid 
sequences with discordant phenotypic measurements, 
three aspects should be investigated. First, the agreement 
between different phenotypic assays should be validated 
or, even better, a standardized phenotypic assay should 
be developed. Second, further research investigating the 
intra-host evolution of HIV-2 with respect to corecep-
tor usage and its impact on viral fitness seems necessary 
to determine whether X4-R5 reversions do occur. Third 
and most importantly, it should be investigated whether 
amino acid substitutions in the V1/V2 region can impart 
the X4-phenotype independently of substitutions in the 
V3, a question for whose resolution more data is required 
[27].
In the following, we discuss the benefits of using 
geno2pheno[coreceptor-hiv2] for HIV-2 core-
ceptor identification. We could show that that 
geno2pheno[coreceptor-hiv2] outperformed the rules-
based approach by Visseaux et  al. [28] on an independ-
ent test set of nine V3 sequences (Table 3). Furthermore, 
the predictive performance of geno2pheno[coreceptor-
hiv2] is at least as high as the predictive performance of 
geno2pheno[coreceptor] for HIV-1, whose established 
cutoffs (EU: 10%/20%, UK: 5.75%, Germany/Austria: 
5–15%) exceed the optimized 5% cutoff that is employed 
by geno2pheno[coreceptor-hiv2] [57–59].
Since geno2pheno[coreceptor-hiv2] is based on an 
SVM, it considers all positions in the V3 loop when pre-
dicting coreceptor usage. Rules-based systems, on the 
other hand, use only a preselected set of discriminatory 
features from the V3 loop to identify coreceptor usage. 
This gives geno2pheno[coreceptor-hiv2] an edge over 
rules-based systems when coreceptor usage can only be 
discerned by considering combinations of multiple sub-
stitutions that together confer the X4-phenotype (Fig. 2).
The predictions by geno2pheno[coreceptor-hiv2] are 
not only accurate, but also interpretable. The web service 
visualizes the model coefficients of an input sequence 
to provide users a comprehensive view of the impact of 
individual positions on HIV-2 coreceptor usage. Addi-
tionally, geno2pheno[coreceptor-hiv2] outputs FPRs, 
Table 3 Results from the validation of the web service on nine additional V3 sequences
Incorrect predictions are marked with an asterisk. ROD10 refers to the HIV2-group A reference strain, which uses both CCR5 and CXCR4 as entry coreceptors. 
Mutations from the ROD10 wildtype sequence are indicated in brackets, where Δ indicates deletions







ROD10 (Wildtype) 0.01 L18X, V3 net charge >6 NA X4-capable X4-capable X4-capable
ROD10 (K29T) 0.01 L18X NA X4-capable X4-capable X4-capable
ROD10 (H18L) 0.03 V3 net charge >6 NA X4-capable X4-capable X4-capable
ROD10 (H23Δ + Y24Δ) 0.01 L18X NA X4-capable X4-capable X4-capable
ROD10 (H18L + K29T) 0.03 NA NA R5* X4-capable X4-capable
ROD10 (H18L + H23Δ + Y24Δ) 0.11 V3 net charge >6 NA X4-capable* R5 R5
ROD10 
(H18L + H23Δ + Y24Δ + K29T)
0.15 NA NA R5 R5 R5
15PTHSJIG 0.36 NA NA R5 R5 R5
15PTHCEC 0.01 L18X, V19K/R, Insertion24, 
V3 net charge >6
Q23R, R28K X4-capable X4-capable X4-capable
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which provide a measure of predictive confidence. More-
over, users are free to select the tradeoff between sensi-
tivity and specificity by adjusting the cutoff for the FPR. 
For example, higher sensitivities (at the cost of more false 
alarms) can be obtained by increasing the FPR cutoff (e.g. 
from 5 to 20%).
Conclusions
geno2pheno[coreceptor-hiv2] is a highly accurate and 
interpretable online tool for the genotypic identifica-
tion of HIV-2 coreceptor usage. Using our method, we 
were able to obtain a better understanding of the V3 
amino-acid substitutions required for the usage of the 
CXCR4 coreceptor and to learn more about the impact 
of the V1 and V2 loops on HIV-2 coreceptor usage. 
geno2pheno[coreceptor-hiv2] can support the clinical 
management of HIV-2 infection because the tool can 
aid physicians in taking treatment decisions and enables 
researchers to undertake large-scale epidemiological 
studies on HIV-2 coreceptor usage.
Methods
Supervised learning with SVMs for HIV‑2 coreceptor usage 
prediction
Our genotypic approach to coreceptor identification is 
based on supervised statistical learning, more specifi-
cally, on classification. Classification requires two types 
of data. The first type of data is a numeric input matrix 
X ∈ RN×p, where N gives the number of observations 
and p gives the number of features. Due to the estab-
lished association between the V3 loop and HIV-2 core-
ceptor usage [17, 27, 29, 30], we used the amino acids of 
the V3 loop as features (N = 126). The input matrix was 
constructed such that each row xi contains the aligned, 
binary-encoded V3 amino-acid sequence of sample i. 
The amino-acid sequences of the V1 and V2 loops were 
also considered as features (N  =  62), but only investi-
gated briefly due to lacking data and smaller predictive 
power of the V1/V2 region.
The second type of data required for binary classifi-
cation is a vector of outcomes Y ∈ ZN , whose entries yi 
contain the numeric representation of the phenotypically 
determined coreceptor usage of sample i, which is also 
called its label. We set yi = −1 for sequences labeled as 
X4-capable and yi = 1 for sequences labeled as R5.
Because SVMs [60] based on the amino-acid sequence 
of the V3 region have already been used successfully for 
identifying the coreceptor usage of HIV-1 [61], we also 
decided to use SVMs. In our setting, SVMs find a vec-
tor of coefficients α and an intercept β0 that define a 
hyperplane maximizing the margin between observa-
tions from the two classes, X4-capable and R5. Predic-











 is a 
kernel function representing the similarity of two V3 
loops xi and xj in Hilbert space [62]. We used LIBSVM 
to determine the optimal hyperplane and transform deci-
sion values to the probability that a V3 originates from an 
X4-capable sequence [63, 64].
Data collection and sample labeling
The majority of the data were retrieved from the Los 
Alamos National Laboratory HIV database by gather-
ing all available HIV-2 V3 sequences with annotations 
of phenotypic coreceptor usage [28, 32, 65–72]. Further 
data points were obtained from the literature [29–31] 
and complemented by our own phenotypic measure-
ments, which were performed as described in the sec-
tions following Section Cells, plasmids, and coreceptor 
antagonists.
To differentiate sequences from R5-tropic strains from 
sequences of viruses that can use CXCR4, each observa-
tion was labeled either as R5 or X4-capable. Isolates for 
which CXCR4 usage was reported (X4-tropic or D/M) 
were annotated as X4-capable and isolates for which 
only the usage of the CCR5 coreceptor was reported 
were annotated as R5. All of the isolates capable of using 
coreceptors other than CCR5 or CXCR4 were also able 
to use the CXCR4 coreceptor and therefore labeled as 
X4-capable.
Next, to obtain a representative training data set for 
statistical learning, the initial data set of 314 genotype-
phenotype pairs was filtered to remove duplicate V3 
sequences. During duplicate removal, we found multi-
ple sequences with discordant annotations of corecep-
tor usage (i.e. sequences sharing the same V3 amino-acid 
sequence but having different phenotypic measure-
ments). For each set of discordant sequences sharing the 
same V3 loop, we considered two possibilities: either to 
include one of the discordant V3 sequences into the data 
set or to exclude all of the sequences (Additional file  1: 
Table S3). In the following, we discuss each decision in 
detail.
Each of the samples sharing the same V3 amino-acid 
sequence as DQ870430 [28, 30, 32, 65–67] and NARI-
12 [28, 30, 31, 65] was phenotyped as X4-capable variant 
only once, while a decidedly larger number of identical 
V3 sequences was phenotyped as R5 (21 and 5 sequences, 
respectively). Hence, we regarded the X4-capable meas-
urements as outliers and the respective sequences were 
included with the R5 label. The sequence with the accession 
GU204945 [32] was identified as X4-capable once and as 
R5 thrice. Hence, due to lacking evidence of actual corecep-
tor usage, this sequence was removed from the data set.
For the V3 sequence with the identifier 310248, usage 
of CCR5 and CXCR4 was reported in one study each. The 
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sequence had been identified in the X4-capable isolate 
310248 [31], but also in an R5 isolate (JN230759/isolate 
29) with the same V3 sequence except for an R/K ambigu-
ity at position 27 [28]. Interestingly, the R5 isolate showed 
a marginal signal for the CXCR4 coreceptor, which was 
discarded because the signal was <5% of the signal for 
CCR5 usage. Further evidence pointing towards the usage 
CXCR4 was presented by Owen et al. [31], who reported a 
minor induction of syncytia for their isolate. Additionally, 
applying a CXCR4 antagonist to cells lacking the CCR5 
coreceptor revealed a reduction in infectivity between 40 
and 90% for this strain [31], which suggests that the isolate 
actually seems to use CXCR4. Therefore, we included this 
sequence as X4-capable in our data set.
After duplicate removal and handling of sequences with 
discordant annotations, 126 genotype-phenotype pairs 
remained of which 74 (58.7%) were labeled as R5 and 52 
(51.3%) as X4-capable (Additional file  1: Table S4).The 
samples in the data set originate from diverse regions. In 
total, 87 (69%) samples were collected in Europe, of which 
42 (48.3%) come from France, 33 (37.9%) from Portugal, 
and 12 (13.8%) from Sweden. All of the 10 (10.3%) Asian 
samples originate from India. Of the 24 (19%) West Afri-
can samples, 15 (60%) were collected in Guinea-Bissau, 5 
(20.8%) in Ivory Coast, 2 (8.3%) in Gambia, and 2 (8.3%) 
in Senegal.
Most isolates in the data set (84.9%) had been geno-
typed as HIV-2 group A. Only a minority of samples 
(13.5%) had been identified as group B and the remain-
ing samples (1.6%) either had been identified as group D 
or had not been genotyped. The group distribution of the 
samples in our data set reflects the global distribution of 
HIV-2 groups: Groups A and B are the most prevalent 
genotypes and the majority of infections are caused by 
group A strains [42, 73, 74].
Sequence alignment
To align the V3 sequences in the data set, we modified 
the Smith–Waterman algorithm for pairwise align-
ments [75] to perform profile alignments in order to 
capture the diversity of the HIV-2 V3 region. In contrast 
to pairwise alignments, profile alignments compare the 
input sequence not with a single reference sequence, 
but with a profile corresponding to the expected amino-
acid frequencies for every position in a genomic region. 
We retrieved all available amino-acid sequences of the 
HIV-2 envelope region from the LANL HIV database 
and selected the V3 region through pattern matching. If 
a sequence exhibited the highly conserved V3 start motif 
(CKRP or CRRP) and the end motif (QAWC), the cor-
responding subsequence was selected. In cases where 
either only the start or end motif could be found, a search 
for the substring of the missing motif was conducted and 
the corresponding subsequence was selected if a sub-
string of the missing motif could be found.
The extracted 1979 V3 amino-acid sequences were 
aligned with ClustalW version 2.1 (using the accurate 
switch and default parameters) [76], which is an estab-
lished tool that is sufficiently accurate for identifying an 
overall amino acid profile of the V3 loop. We then com-
puted the frequency of each amino acid for every align-
ment position to obtain a profile of the V3 loop. The 
profile alignment of the V3 amino-acid sequences was 
performed by computing the alignment scores under 
consideration of both, the frequency of amino acid sub-
stitutions given by the alignment profile and an amino 
acid substitution matrix [77].
Sequence encoding
Let AA be the set of 20 amino acids augmented with 
the gap character “-”. To obtain the input matrix X, each 
aligned V3 amino-acid sequence si with |si| = 39 ∀i was 
encoded as a feature vector xi with 21 * 39 = 819 dimen-
sions. Let xi,j[c] denote whether the character c  ∈  AA 
appears at position j in the V3 loop of observation i. To 
deal with ambiguous positions, we disambiguate IUPAC 
ambiguity codes and define si,j as the set of unambigu-
ous amino acids occurring at position j in the i-th input 
sequence. For each position j in an aligned sequence si, 
we uniformly distribute the weight among all observed 
amino acids and set the value of non-observed amino 
acids to 0:
Note that xi,j[c]  =  1 for unambiguous positions with 
si,j = {c} and |si,j| = 1.
Model selection and validation
Based on the input matrix X containing the 126 aligned 
and encoded V3 amino-acid sequences as well as the vec-
tor of outcomes Y  denoting phenotypic coreceptor usage, 
we trained several SVMs to identify which SVM per-
forms best in terms of the AUC of the receiver operating 
characteristic [78]. The SVM parameter ν was varied in a 
range from 0.1 to 0.4 (higher values were not considered 
due to infeasible optimization problems) and different 
kernel functions (linear, radial basis function, polyno-
mial, and edit kernel [79]) were used to form predictions.
To evaluate the performance of the SVMs, we con-
ducted 10 runs of tenfold CV [80]. Additionally, to 
determine the expected performance of our approach 
taking into account the model selection procedure, 





xi,j[c] = 0 ∀c /∈ si,j
Page 11 of 16Döring et al. Retrovirology  (2016) 13:85 
interlaced runs of CV were performed. In the inner CV 
run, we computed the AUCs resulting from the predic-
tions of each model and selected the model and kernel 
parameters maximizing the AUC. In the outer CV run, 
we trained a model with the selected parameters on the 
inner CV training data and predicted the outcomes of 
samples contained in an independent fold. After all outer 
fold predictions had been computed, the overall model 
performance was determined.
To compare the performance of the rules-based 
approach from Visseaux et al. [28] with our method, we 
set up a test data set (N = 84), whose observations where 
not used to identify discriminatory features by Visseaux 
et  al. This test set was formed to determine the predic-
tion performance of their model on independent data. 
We evaluated whether there exists a significant difference 
between the rules-based approach and our method by 
applying McNemar’s test.
McNemar’s test
McNemar’s test [40] is based on the values contained in 
a 2 × 2 confusion matrix and can be used to determine 
whether two classifiers perform differently. The test can 
be applied on paired dichotomous variables that are 
mutually exclusive and identifies if there exists a differ-
ence in the distribution of the marginal frequencies of 
each outcome. In our case, we applied the test to the pre-
dicted and phenotypically determined coreceptor usages 
(R5/X4-capable). To compare the performance of SVMs 
for coreceptor prediction with the rules-based approach 
from Visseaux et  al. [28], we computed the number of 
samples that were correctly or incorrectly predicted by 
each method and constructed a 2 × 2 contingency table. 
The null hypothesis assumes that both approaches have 
the same ratio of incorrect predictions. Let p indicate 
the probability of a certain outcome. Given the entries in 
Additional file 1: Table S5, the underlying assumption is 
that pa +  pb =  pa +  pc and pc +  pd =  pb +  pd. Hence, 
the null hypothesis is that H0 : pb = pc and, alternatively, 
H1 : pb �= pc.
The test statistic, X2 = (b−c)
2
b+c
, can be rejected when 
X2 is sufficiently large, that is, indicates a significant dif-
ference between the predictive performance of both 
approaches.
Transformation of decision values to FPRs
We used SVMs that transform decision values to prob-
abilities that indicate whether a V3 loop originates from 
an X4-capable virus (X4-probabilities) [64]. Although 
these probabilities give a measure of confidence, they 
does not afford insights into the accuracy of predictions, 
which is crucial for clinical applications, however. Since 
FPRs provide a useful measure for the confidence of a 
prediction and because they are an established measure 
for the quantification of HIV-1 coreceptor usage [61], 
we transformed the predicted X4-probabilities to FPRs. 
Here, the FPR indicates the estimated rate at which an 
R5-tropic virus would be falsely predicted as X4-capable 
when using a given X4-probability as a cutoff for the two 
classes.
To transform X4-probabilities to FPRs, we constructed 
a mapping from predicted X4-probabilities to FPRs dur-
ing the training stage. Each predicted X4-probability was 
used as a cutoff for classifying samples once: All samples 
with X4-probabilities below the cutoff were assigned R5 
and all samples with X4-probabilities greater or equal to 
the cutoff were assigned X4-capable. This cutoff-depend-
ent class assignment in combination with the phenotypic 
labels for each observation yielded a 2 ×  2 contingency 
table indicating false positives (FP) and true negatives 
(TN), from which we could compute the FPR as
which results from applying every predicted X4-prob-
ability as a cutoff once. Using this transformation, low 
FPRs indicate confident predictions of X4-capable vari-
ants, while high FPRs designate R5-tropic viruses.
Determining the impact of amino acids in the V3 loop 
on HIV‑2 coreceptor usage
LIBSVM outputs a weight vector α∗ ∈ Rn. Its entries 
α∗i = αˆiyi indicate the estimated weight αˆi of each sup-
port vector x∗i  scaled by the corresponding outcome yi. 
The coefficients β ∈ Rp, which reflect the impact of indi-
vidual amino acids in the V3 loop on coreceptor usage, 
can be determined by β = α∗T X∗. Hence, given a new 
input sequence, xi ∈ Rp, we can find its amino-acid spe-
cific weights b(i) as the element-wise vector product of 
the coefficients and the encoded input features such 
that b(i) = xi ∗ β, which can be visualized in terms of a 
bar plot indicating the role of individual amino acids for 
HIV-2 coreceptor usage.
Modified feature encoding used 
by geno2pheno[coreceptor‑hiv2]
To predict the label of a new input sequence, its V3 is 
modified in two ways in order to improve predictive per-
formance. The first modification concerns gaps in the 
sequence and the second relates to ambiguous positions.
Errors during sequencing or problems with the align-
ment can lead to the introduction of gaps in the V3 loop, 
which have no functional meaning and can bias predic-
tions. Therefore, our approach detects gaps that are not 
functionally relevant and are likely to represent artifacts 
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corresponds to character c at sequence position j and let 
ε = 0.01.
For every position j with c = −, we consider the model 




∣ < ε, the 
gap does not affect HIV-2 coreceptor usage according to 
the model and it can be replaced with the encoded con-
sensus amino acid a from position i contained in the V3 
alignment profile by setting xj[c]  =  a before predicting 
coreceptor usage for the input sequence. Otherwise, if 
|βj(c)| ≥ ɛ, no modification is necessary.
Ambiguous positions in Sanger sequencing of viral 
populations indicate the presence of multiple viral vari-
ants within the same host. These variants might use dif-
ferent coreceptors for cell entry and a single position 
might indicate amino acids representative of both, R5 
and X4-capable viruses. To be more sensitive towards 
X4-capable variants, every ambiguous position in an 
input sequence is replaced by the disambiguated amino 
acids that are most strongly associated with X4-capa-
bility. Note that, since the labels for training the SVM 
were encoded by −1 for X4-capable and 1 for R5, posi-
tive coefficients designate features associated with R5 and 
negative coefficients designate features associated with 
X4-capable.
For every ambiguous sequence position j with 
observed amino acids sj, we set sj = arg minc∈sj βj(c) in 
order to construct a non-ambiguous sequence that is 
more predictive of X4-capability. The fact that this worst-
case scenario sequence might not exist in  vivo when a 
sequence exhibits multiple ambiguous positions is only 
a minor concern. This is due to the following reason. 
Assume that a viral population consists of an R5- and an 
X4-capable quasispecies, which means that the predic-
tion should be X4-capable. In this case, every ambiguous 
position should contain an amino acid representing the 
X4-capable variant such that for every ambiguous posi-
tion j we have βj(c) ≤  0 for all amino acids c occurring 
at the ambiguous position. Selecting the observed amino 
acid whose weight contributes most strongly to X4-capa-
bility means choosing the character c obtaining the most 
negative weight βj(c). Consequently, the decision value of 
observation x, f(x), enhances the prediction of X4-capa-
ble variants by reducing the decision value. The same 
logic can be applied to two distinct X4-capable vari-
ants. Assume now that there exist two variants that use 
only the CCR5-coreceptor. In this case, the prediction 
should be R5 and the weights of ambiguous positions 
should be positive, because no amino acids associated 
with X4-capability are observable. Hence, the worst-case 
choice results in min βj(c) ≥ 0 for all characters c at every 
ambiguous position j, which does not enhance the pre-
diction of X4-capable and thus does not influence the 
likelihood of a correct prediction of R5 when the decision 
boundary is set to 0. Even for decision boundaries at 
values above zero, selecting the worst-case amino acid 
would only have a marginal effect on the prediction in 
the described scenario, because of the larger number and 
greater impact of non-ambiguous positions with positive 
weights.
Cells, plasmids, and coreceptor antagonists
HEK293T cells were purchased from American Type 
Culture Collection (Rockville, MD). The following rea-
gents were provided by the AIDS Research and Reference 
Reagent Program, National Institutes of Health: TZM-
bl cells [33, 34, 81–83], TAK-779 [84, 85], and bicyclam 
JM-2987, a hydrobromide salt of AMD-3100 [86–88]. 
The wild-type pROD10 plasmid was a gift from Keith 
Peden [89]. HEK293T and TZM-bl cells were cultured in 
complete growth medium consisting of Dulbecco’s modi-
fied eagle medium (DMEM) supplemented with 10% of 
fetal bovine serum, 100 U/ml of penicillin–streptomycin, 
2  mM of l-glutamine, 1  mM sodium pyruvate, and 1× 
of MEM non-essential amino acids (Gibco/Invitrogen, 
USA). All cell cultures were maintained at 37 °C in 5% of 
CO2.
Virus isolates
Two new primary isolates, 15PTHSJIG and 15PTHCEC, 
were obtained from HIV-2-infected Portuguese patients 
by cocultivation with peripheral blood mononuclear cells 
from seronegative subjects, as described previously [90]. 
In addition, six new HIV-2ROD10 mutants were analyzed 
that contained the following mutations in the V3 loop: 
H18L, H23Δ  +  Y24Δ, K29T, H18L  +  H23Δ  +  Y24Δ, 
H18L + K29T, and H18L + H23Δ + Y24Δ + K29T [91]. 
HIV-2 ROD10 mutants were obtained by transient trans-
fection of HEK293T cells. Transfections were performed 
with 10 μg of DNA in a 100 mm tissue culture dish, using 
the jetPrime transfection reagent (Polyplus) according to 
the instructions of the manufacturer. Cell culture super-
natants were collected 48  h post-transfection, filtered, 
and stored at −80 °C.
The 50% tissue culture infectious dose (TCID50) of 
each isolate was determined in a single-round viral infec-
tivity assay using a luciferase reporter assay with TZM-
bl cells. First, 10,000 TZM-bl reporter cells were seeded 
in 96-well tissue culture plates and incubated overnight. 
On the next day, the growth medium was removed and 
replaced by 200  μl of fresh growth medium supple-
mented with 19.7 μg/ml of DEAE-dextran. A total of 
100  μl of virus supernatant was added to the first well, 
from which serial threefold dilutions were prepared in 
the next wells. The assay was performed in quadruplets. 
After 48 h, luciferase expression was quantified by meas-
uring luminescence with the Pierce Firefly Luciferase 
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Glow Assay Kit (Thermo Fisher, USA) and the Infinite 
M200 luminometer (TECAN), according to manufac-
turer’s instructions. Control wells containing only target 
cells and growth medium were used to measure back-
ground luminescence. The TCID50 was calculated using 
the statistical method of Reed and Muench [92].
Phenotypic determination of coreceptor usage
CCR5 and CXCR4 coreceptor usage was determined in 
a single-round viral infectivity assay with TZM-bl cells 
[16, 35]. First, 10,000 TZM-bl reporter cells were seeded 
in 96-well tissue culture plates and incubated overnight. 
On the next day, the growth medium was removed and 
the cells were incubated for 1 h (at 37 °C in 5% CO2) with 
growth medium either in the presence or in the absence 
of excessive amounts of the CCR5 antagonist TAK-779 
(10  μM) and/or of the CXCR4 antagonist AMD3100 
(1.2  μM). A fixed amount of virus supernatant, cor-
responding to 200 TCID50 was added to each well and 
cells were cultured with a total volume of up to 200 μl of 
growth medium in the presence of 19.7 μg/ml of DEAE-
dextran. After 48  h, luciferase expression was quanti-
fied by measuring luminescence with the Pierce Firefly 
Luciferase Glow Assay Kit (Thermo Fisher, USA) and 
the Infinite M200 luminometer (TECAN), according 
to manufacturer’s instructions. Control wells contain-
ing only target cells and medium were used to measure 
background luminescence. A viral population was classi-
fied as R5-tropic when viral infectivity was inhibited in 
the presence of TAK-779 but unaltered in the presence of 
AMD3100, and, as X4-tropic when infectivity was inhib-
ited in the presence of AMD3100 but unaltered in the 
presence of TAK-779. When infectivity was completely 
inhibited only by the simultaneous presence of TAK-779 
and AMD3100, the virus population was classified as 
dual/mixed (D/M) for viral isolates or as R5/X4 tropic for 
ROD10 mutants.
Additional file
Additional file 1: Figure S1. Distribution of X4-probabilities predicted 
by geno2pheno[coreceptor-hiv2]. Blue bars indicate sequences labeled as 
R5, while red bars indicate sequences labeled as X4-capable. Figure S2. 
Estimated TPRs versus FPRs for predictions from geno2pheno[coreceptor-
hiv2]. Each dot indicates a prediction of HIV-2 coreceptor usage and the 
color of the dot indicates the corresponding phenotypic coreceptor 
usage (blue: R5, red: X4-capable). Table S1. Predictive performance of 
the rules-based approach from Visseaux et al. on the test set. Table S2. 
Predictive performance of individual rules identified by Visseaux et al. 
ordered by decreasing balanced accuracy as determined on the test set. 
Table S3. Overview of observations with identical V3 loops, but discord-
ant annotation of phenotypic coreceptor usage. Table S4. Distribution 
of class labels and HIV-2 groups in the data set. Table S5. Structure of the 
2x2 contingency table required for McNemar’s test.
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